- With the anticipation of a 2Q program update, Verastem Oncology (NASDAQ:VSTM) announced that its interim analysis findings for the RAMP 201 program for recurrent low-grade serous ovarian cancer (LGSOC) continue evaluation in both monotherapy and combination regimens.
- With incremental updates from ASCO, reiterated KOL enthusiasm, and more updates are upcoming in 2022 on a longer runway, RBC Capital continues to like the VSTM setup.
- The company plans to complete enrollment of all four trial cohorts in the second half of this year.
- Related: Truist Sees 350% Upside On This Cancer-Focused Biopharma Stock - Read Why.
- It has reiterated the Outperform, Speculative Risk rating, and a price target of $5.
- RBC Capitals believes VSTM has exhibited differentiating safety profile exhibited thus far, all of which it finds reassuring.
- The analysts noted that around 6% had discontinued the trial based on treatment-related adverse events compared to ~30% for tyrosine kinase inhibitors' current standard of care.
- However, the update has generated interest in the clarity around the planned regulatory interactions, which are still pending and will guide go-forward dosing and trial design.
- Price Action: VSTM shares are up 6.15% at $1.30 during the market session on the last check Tuesday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
RBC Says Verastem Interim Analysis In Ovarian Cancer Reinforces Enthusiasm
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks